RSS

Tagrisso (osimertinib)

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Tagrisso (osimertinib) as a first-line treatment of patients with inoperable or recurrent epidermal growth factor mutation-positive non-small cell lung cancer Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

A positive opinion has been adopted by the CHMP of the European Medicines Agency, recommending a change to the terms of the marketing authorisation for AstraZeneca’s Tagrisso (osimertinib) to include first-line treatment. Read more

News